India Marks Milestone: 80 Lakh HPV Vaccine Doses Administered in Cervical Cancer Fight

New Delhi: In a significant advancement for public health, India’s national cervical cancer prevention drive has reached a pivotal milestone, with over 80 lakh doses of the human papillomavirus (HPV) vaccine administered since the campaign’s inception in February 2026. This nationwide effort is designed to immunize 14-year-old girls against HPV, the primary driver of cervical cancer, representing a critical shift in the country’s strategy to combat one of the most common malignancies affecting women.

A Targeted Approach to Public Health

The national initiative focuses on providing a single-dose HPV vaccine free of charge to girls aged 14. By ensuring broad access through government health facilities, the government aims to cover an estimated target population of 1.2 crore adolescent girls. The program is entirely voluntary, requiring explicit parental consent, which has been a cornerstone in ensuring community trust and high uptake across diverse states and union territories.

Experts have long argued that early immunization is the most effective shield against cervical cancer. By targeting the 14-year-old age group, the health ministry hopes to break the chain of transmission before exposure to the virus occurs, potentially saving thousands of lives in the decades to come.

Regional Progress and Vaccination Leaders

The geographic distribution of the vaccination drive reveals varying levels of success and public engagement across the country. Uttar Pradesh has emerged as the frontrunner in absolute numbers, having successfully administered over 22 lakh doses.

Meanwhile, some regions have set benchmarks for efficiency. Both Gujarat and Mizoram have achieved the remarkable feat of 100% coverage, signaling successful coordination between local health workers, schools, and parental awareness campaigns. Other states are not far behind; Bihar and Assam have demonstrated strong momentum, with both reporting over 90% coverage.

Karnataka has also reported robust participation with an 85% coverage rate. Meanwhile, a cluster of states—including Chhattisgarh, Sikkim, Kerala, Telangana, and Odisha—have reached the 60% threshold. These figures highlight the varying logistical challenges in reaching adolescents in different demographic landscapes but underscore a collective national push toward better reproductive health outcomes.

Why the HPV Vaccine Matters

Cervical cancer remains a major health concern for women in India. The introduction of the HPV vaccine into the national immunization schedule is a transformative step that aligns India with global standards for cervical cancer elimination. The shift to a single-dose regimen has been particularly lauded by health professionals for its ease of administration and its potential to reduce the logistical burden on the healthcare system while simultaneously improving compliance among the target demographic.

As the campaign continues, the focus is expected to shift toward those areas yet to hit the 80% mark, ensuring that rural and marginalized communities are not left behind. With sustained momentum and public support, the national HPV drive is poised to make cervical cancer a preventable tragedy rather than a persistent threat to the health and future of young women across the nation.

Disclaimer: This content is auto-generated for informational purposes only.

Source: Read Original News